Indeed, clinical trials testing an agent to reverse cachexia combined with an immune checkpoint inhibitor to treat advanced lung cancer patients is relevant since the treatment with ghrelin analog affects T cell development and proliferation [38]. This evidence concerns the gene GHRL and lung cancer.